Tag Archives: Drug Development

Lost a Billion? Let’s Celebrate!

Posted on April 8, 2024 by Eugene Ivanov

This image was created with the help of Microsoft designer As every popular topic, innovation is a powerful magnet for clichés — and, let’s face it, some of them suck. For example, I’m not sure that mixing innovation and DNA … Continue reading →

Posted in Health Care, Innovation | Tagged Celebrating Failure, Drug Development, Phase III clinical trials | Leave a comment

Are ideas plentiful and cheap?

Posted on September 22, 2017 by Eugene Ivanov

We often hear: ideas are cheap. “Ideas are a dime a dozen. People who implement them are priceless,” claims a 2013 article in Forbes. As a prevailing point of view has it, innovative ideas are plentiful; it’s the idea … Continue reading →

Posted in Crowdsourcing, Innovation | Tagged Crowdsourcing, Drug Development, Innovation, Moore’s Law | 1 Comment

Balancing startup success and failure: how VC investors can tip the scales

Posted on September 10, 2017 by Eugene Ivanov

Recently, I’ve come across an interesting paper, “Tolerance for Failure and Corporate Innovation,” published in 2011 by Xuan Tian of Indiana University and Tracy Yue Wang of University of Minnesota. Tian and Wang studied the relationship between venture capital (VC) … Continue reading →

Posted in Innovation, Startups | Tagged Corporate Venture Capital Groups, Drug Development, Entrepreneurship, Innovation, innovation ecosystems, Startups | Leave a comment

The first rule of crowdsourcing: know what you want, understand what you need

Posted on October 6, 2016 by Eugene Ivanov

I like to argue (for example, here) that the most important factor that defines the ultimate success or failure of any crowdsourcing campaign is the ability to properly identify and articulate the problem–technological, business or social–that the crowd will be … Continue reading →

Posted in Crowdsourcing | Tagged Crowdsourcing, Drug Development, HTS, Innovation, Innovation Management, innovation tools, Open Innovation, Open Innovation Tools, R&D processes | 2 Comments

Get it right: how to help startups succeed

Posted on February 22, 2016 by Eugene Ivanov

Given the increasingly important role startups and other small businesses play in today’s economy, supporting them should be considered a policy that will have a profound positive effect on the global economy. From this perspective, pinpointing factors casing startups fail is … Continue reading →

Posted in Startups | Tagged Clinical Trials, corporate VCs, Culture of Innovation, Drug Development, Entrepreneurship, Innovation, Innovation Management, R&D processes, startup accelerators, startup incubators, Startups, U.S. Small Business Administration, Wharton’s Mack Institute for Innovation Management | 2 Comments

The Art of Killing (a Project)

Posted on October 1, 2015 by Eugene Ivanov

(This post first appeared on the Front End of Innovation Blog) As innovation becomes an increasingly popular topic in business literature, social media and public discussions, it also turns into a powerful magnet for clichés. One of the most used, if … Continue reading →

Posted in Portfolio Management | Tagged “kill the losers", “pick the winners”, Celebrating Failure, Culturevate, Dare to Try, Drug Development, Entrepreneurship, Institute for International Research, Intrapreneurship, Portfolio Management, Project management, Tata Group, The Corporate Intrapreneur Summit | 5 Comments

Do you know the age of your child? (Toward the biomarkers of childhood)

Posted on October 28, 2014 by Eugene Ivanov

How often, when taking an over-the-counter drug, did you read the following note on the label: “adults and children 12 years of age and over: one tablet; children under 12 years of age: ask a doctor”? Pretty often, I guess. And … Continue reading →

Posted in Crowdsourcing, Global Innovation, Health Care | Tagged adolescents, biomarkers, biomarkers of childhood, childhood obesity, Crowdsourcing, Drug Development, infants, Innovation, Innovation Management, juvenile justice system, neonates, Obesity, Open Innovation, open innovation services providers, Open Innovation Tools, OTC, Pediatric Care, Pediatric patient, Pediatrics, preschoolers, San Mateo County, school-agers, toddlers | Leave a comment

What Can Crowdsourcing Do?

Posted on August 21, 2014 by Eugene Ivanov

I’m often asked questions about crowdsourcing. Usually, they’re revolving around this central theme: what can crowdsourcing do? Can crowdsourcing solve this problem? Can crowdsourcing solve that problem? On occasion, a more perceptive question is posed: can crowdsourcing define a problem? … Continue reading →

Posted in Crowdsourcing | Tagged Crowdsourcing, diabetes, Drug Development, Harvard Catalyst, Harvard Medical School, Innovation, Open Innovation, Open Innovation Tools, Type 1 diabetes, unmet medical needs | 3 Comments

All Innovation Is Local

Posted on August 15, 2014 by Eugene Ivanov

I like this phrase: all politics is local. Ascribed to the late Speaker of the U.S. House of Representatives Tip O’Neill this phrase means that all political decisions, regardless of their purpose and scale, must take into account the interests … Continue reading →

Posted in Health Care | Tagged Clinical Trials, consumer-centric healthcare, Crowdsourcing, disease advocacy organizations, Drug Development, druggable molecular targets, FDA, Innovation, Innovation Management, Open Innovation, patient groups, Phase III clinical trials, R&D processes, rapid prototyping, Tip O’Neill, Transparency Life Sciences, unmet customer needs, unmet medical needs, VOC, voice of the customer | Leave a comment

Should We Celebrate Failure Worth A Billion?

Posted on August 5, 2014 by Eugene Ivanov

As every popular topic, innovation is a powerful magnet for clichés. Some of them obliterate more than illuminate. For example, I’m not sure that mixing innovation with DNA is a good idea. Though I kind of understand what Clayton Christensen … Continue reading →

Posted in Portfolio Management | Tagged cancer, Clayton Christensen, Clinical Trials, Drug Development, FDA, Innovation, Phase III, The innovator’s DNA | 11 Comments